Monday 30 January 2017

Robotic Rehabilitation and Assistive Technologies Market Forecasts up to 2024, Research Reports

The robotic rehabilitation and assistive technologies market accounts for rehabilitation robots and assistive technology robots. A robot is a mechanical and virtual intelligent agent that is guided by a computer program. A robot is an electromechanical machine which performs a task automatically or guided by a remote control. Robotics is the branch of technology which deals with the design, construction, operation and application of robots, while the field of research devoted to extending rehabilitation through the implementation of robotic devices is called Rehabilitation Robotics. A rehabilitation robot guides movement of a disabled person or elderly person with the intention of improving sensorimotor functions like arm, hand, leg and ankle. An assistive robot performs a task for the benefit of an elderly person or a patient with disability. These robotic devices are helpful for millions of people who desire to conquer the disability.
Robotic Rehabilitation and Assistive Technologies Market Segmentation
The global market for robotic rehabilitation and assistive technologies, on the basis of product type, has been segmented into assistive robots, prosthetics, orthotics, therapeutic robots and exoskeleton robotic systems. The global market for robotic rehabilitation and assistive technologies is also segmented as fixed base robots and mobile robots. Fixed based robots can be placed nearby a patient for medication, feeding and other tasks. Mobile robots can be used for mobility support and for fetching or carrying. During the forecast period from 2016 to 2024, worldwide market is poised to achieve significant growth as a result of growing application of robotic devices across the rehabilitation centers and healthcare facilities offering rehabilitation to patients suffering from physical disabilities such as spinal cord injury, cerebral palsy, rheumatoid arthritis and stroke.
Robotic Rehabilitation and Assistive Technologies Market Drivers
Worldwide increasing elderly population along with growing prevalence of conditions such as spinal cord injury, cerebral palsy, rheumatoid arthritis, dementia and other age-related disabilities are playing a key role in driving the global market for robotic rehabilitation and assistive technologies. According to the Centers for Disease Control and Prevention, approximately 200,000 people are living with spinal cord injury in the U.S. and the annual incidence has been estimated at 15 to 40 new cases per million population, nearly 12,000 to 20,000 new cases in a year. The Centers for Disease Control and Prevention stated in November 2013 that approximately 52.5 million U.S. adults suffer from arthritis, nearly 23% of the total adult population. According to a U.S. based website called MyChild at CerebralPalsy.org, around 764,000 children and adults have cerebral palsy in the U.S. Of which, nearly 500,000 are aged below 18 years. Globally, the prevalence of dementia was estimated around 35.6 million in 2010 that is expected to reach approximately 65.7 million by 2030 and nearly 115.4 million in 2050. More than 50% of all people with dementia lived in developing and poor economy countries in 2010 which is expected to exceed 60% by the end of 2030. Such high prevalence of conditions is expected to drive the demand for rehabilitation robots and assistive robots across rehabilitation centers, hospitals and other healthcare centers. High cost of robotic devices is one of the major factors that is restraining the market growth, especially in countries with low and medium economy.
In terms of geography, the global robotic rehabilitation and assistive technologies market has been categorized into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). North America and Europe represented the first and second largest markets for robotic rehabilitation and assistive technologies in 2013. It was mainly due to well established healthcare infrastructure of these regions.
Robotic Rehabilitation and Assistive Technologies Market Key Players
Intuitive Surgical Inc., Accuray, Inc., Mazor Robotics Ltd. and Health Robotics S.R.L. are some major players of this market.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Posted by at No comments:
Labels: , ,

Alpha Mannosidosis Market is expected to progress at a CAGR of 11.9% between 2017 and 2024

Global Alpha Mannosidosis Market: Snapshot
Alpha mannosidosis is an inherited medical condition tissues and organs of the human body to function in abnormal ways. The commonly seen dysfunctions in patients suffering from this disease are distinctive facial features, intellectual disability, and skeletal abnormalities. Some of the other facial features seen amongst patients are a protruding forehead, large head, rounded eyebrows, low hairline, outsized ears, expanded jaw, flattened bridge of the nose, overgrown gums, widely spaced teeth, and outsized tongue. Though this is a rare disease, a definite rise in the population has increased the number of patients thereby augmented the demand for drugs required for treating alpha mannosidosis.
Owing to this reason, the opportunity in the global market is expected to be worth US$21.8 mn by the end of 2024 as against US$2.6 mn in 2015, as the market progresses at a CAGR of 11.9% between 2017 and 2024. The global market for alpha mannosidosis is being driven factors such as market exclusivity being enjoyed by orphan drugs, fee reductions, tax credits, increasing investment in the rare disease treatment, and premium pricing.
BMT Emerges as Leading Therapy for Treating Alpha Mannosidosis
Statistics show that alpha mannosidosis affects one in every 10, 00,000 people across the globe. The two types of treatment available for treating this disease are bone marrow transplant (BMT) and enzyme replacement therapy (ERT). Currently, bone marrow transplant (BMT) is the most popularly used treatment for patients. However, ERT is also picking up pace as the manufacturers operating in the segment are vying for commercial roll out of therapies. A promising therapy for lysosomal storage diseases (which are similar to alpha mannosidosis) is an enzyme replacement therapy (ERT). The therapy introduces the missing enzyme in the patient’s blood stream, which is absorbed by the cells then delivered to the lysosomes.
Asia Pacific and North America Show Promise of Steady Growth during Forecast Period
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to hold a dominant share in the market in 2017. This dominance will be attributable to the growing awareness about the disease in developing countries. Presently, the Government of Australia has implemented a national plan for helping patients with rare diseases to reduce the mortality rate due to these diseases. The plan aims to raise awareness about the burden of rare diseases among patients, its impact on social life, and healthcare professionals.
North America alpha mannosidosis market is also expected to witness a remarkable growth rate in the coming years. The orphan drug law will boost the new drug discovery efforts as it aims to offer monetary as well as non-financial benefits to manufacturers. The biggest incentive offered North America is a 50% cut the cost incurred for conducting clinical trials, seven years of market exclusivity for orphan drugs, eligibility for federal research grants, and waiver of user fees.
The leading players operating in the global alpha mannosidosis market is Zymenex. The company currently focusses on research and development of biologics that are designed to fight rare and life-threatening genetic diseases. The company has developed recombinant enzyme indicated for patients with alpha mannosidosis, which is known as Lamazym (velmanase alfa) in the market.
Posted by at No comments:
Labels: , , ,

Dental Consumables Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024

Global Dental Consumables Market: Snapshot
The growing number of dental issues across the world are fuelling the demand for dental consumables. These consumables are predominantly used for tooth restoration, treating dental impairments, and related gingival tissues. The global dental consumables market has been thriving in recent years due to the increasing dental tourism in developing countries. Citing these reasons, analysts predict that global dental consumables market will be worth US$33.4 bn by the end of 2024 from US$19.6 bn in 2015. The overall market between 2016 and 2024 is expected to rise at a CAGR of 6.1%.
Several emerging economies such as Turkey, Hungary, and India are expected to offer lucrative opportunities to the global market in the coming years. The low cost of labor, less government intervention, effective dental treatments, and improving services are expected to draw in a large number of patients for dental treatments. The market is also thriving due to the remarkable improvements in the quality of dental implants, which has assured several patients to opt for dental treatments. Rising disposable incomes, improving lifestyles, and growing awareness about oral healthcare are also expected to drive the global dental consumables market in the next few years.
Resemblance of Crowns and Bridges to Natural Teeth Make them Most Preferred Choice of Dental Consumables
In terms of products, the global market is segmented into retail dental care essentials, crowns and bridges, dental biomaterials, orthodontics, dental implants, dental consumables, endodontics, and periodontics. Of these, the crowns and bridges segment has been leading the global market and is expected to remain dominant all throughout the forecast period. These devices are used for creating a protective layer over damaged part of the tooth. The segment is receiving a significant boost due to introduction of advanced technologies such as CAM and CAD. Analysts anticipate that the market could also benefit from the rising awareness about cosmetic dentistry, improving life expectancy, and a huge pool of geriatrics across the globe. The report also suggest that stability of crowns and bridges and their resemblance to natural-looking tooth are also expected to drive the demand for this segment. Furthermore, the rising cost of metals has negatively impacted the metal-based crowns and bridges, tilting the demand toward newer ones.
Improvements in Oral Healthcare across Europe keeps Region in the Lead
In terms of geography, the global dental consumables market is segmented into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa. Europe is the frontrunner in the global market due to the ever-increasing pool of geriatrics. The growing concerns for oral health care are expected to keep Europe growing at a steady CAGR in the global dental consumables market during the forecast period. The growing funding for improving and expanding oral health care facilities across Europe is also expected to benefit this regional market.
On the other hand, Asia Pacific is also expected to show a steady growth rate in the coming years. The emergence of the middle class is the primary growth driver for this regional market. The booming dental tourism in Asia Pacific is estimated to keep up the demand for dental consumables in the coming years. Furthermore, improving disposable incomes, access of oral health care, and growing awareness will also boost the growth of the regional market.
Posted by at No comments:
Labels: , , ,

Smart Medical Devices Market Outlook and Forecast up to 2024

Global Smart Medical Devices: Snapshot
Smart medical devices have gained traction in the recent past due to the multitude of benefits they provide to the patient and the caregiver. These devices have radically changed the way a disease is managed, by storing copious amounts of data in a logical format to draw insightful inferences. From understanding patterns of diseases or health issues, smart medical devices have largely helped users to keep an efficient tract of their health and fitness regime. Owing to these reasons, the global smart medical devices market is expected to soar at a CAGR of 7.8% to reach US$66.1 bn by 2024 as compared to US$33.7 bn in 2015.
Convenience of Tracking Health Issues through Smart Medical Devices Bodes Well for Global Market
Smart medical devices are being used as important tools by physicians to detect various disease by monitoring vital signs. Chronic disease such as hypertension and diabetes have thus received a fresh perspective from both the medical industry as well as the patients. From a broader perspective, these devices have drastically reduced the workload for healthcare providers by closely monitoring patient health and taking quick action in case of any major change in the readings. The report predicts that the demand for smart medical devices will be attributable to the growing pool of geriatrics, who are prone to a wide range of illnesses. Furthermore, the rapid technological advancements in the fitness devices have also lured in a large base of consumers who are interested in monitoring their heart rate, calorie intake, and the number of calories burned. The user-friendliness of these devices is also expected to fuel the uptake of smart medical devices in the coming few years.
Diagnostic and Monitoring Devices to Remain Popular as Inclination toward Fitness Increases
The various products available in the smart medical devices market are On the basis of product, the global market is segmented into therapeutic devices, diagnostic and monitoring devices, and injury prevention and rehabilitation devices. Of these, the diagnostic and monitoring devices segment is expected to dominate the global market. Growing awareness toward fitness is expected to drive the uptake of these devices. The quick and easy accessibility to fitness prompts, near-accurate monitoring of health condition such as diabetes and blood pressure, and wide availability of devices in varying price range is expected to work in favor of this segment.
Improving Medical and Healthcare Services in North America Drive Regional Market
In terms of geography, the global smart medical devices market is segmented into North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. North America is expected to exhibit excellent growth rate in the coming years. The adoption of technology in the region and its acceptability amongst the overall population is estimated to benefit the regional market. The ongoing upgradation of medical and healthcare services in the region have also played a crucial role in swift sales of smart medical devices all across North America.
Some of the leading players operating in the global smart medical devices are Abbott Laboratories, Apple Inc., Dexcom, Inc., Fitbit, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Medtronic plc, NeuroMetrix, Inc., Samsung Electronics Co., Ltd, and Sonova. F. Hoffmann-La Roche Ltd. These players are expected to retain the lead in the coming years due to their penetration in emerging economies and product innovation. The growing investments in the development of sophisticated products are also anticipated to drive the soaring revenues of these players in the coming few years.
Posted by at No comments:
Labels: , , ,

Pulmonary Drugs Market: Combination Drugs Remain Favorite amongst Medical Professionals

Global Pulmonary Drugs Market: Snapshot
This report on pulmonary drugs studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drugs market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
Global Pulmonary Drugs Market: Segmentation
The global pulmonary drugs market has been studied based on major drug classes, application segments, major distribution channels, and regional as well as national markets. Based on drug classes, the global market has been categorized into eight major segments: Inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others. Based on application, the global market has been categorized into five segments: Asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into four key segments: hospital pharmacies, retail pharmacies, drug stores, and e-commerce.
The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.
Global Pulmonary Drugs Market: Scope
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/applications/distribution channels/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drugs market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drugs market.
Global Pulmonary Drugs Market: Geographical Outlook
Geographically, the pulmonary drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drugs market has been further categorized into major product, application, and end-user segments considered within the scope of the study. Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.
Key Players Mentioned in the Report are:
The report also profiles key players operating in the pulmonary drugs market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals, Inc. and others
Posted by at No comments:
Labels: , , , ,

Pyrogen Testing Market is expected to surge at a CAGR of 11.9%

Global Pyrogen Testing Market: Snapshot
The global pyrogen testing market has been witnessing a rapid growth rate in recent years as the pharmaceutical, medical devices, and biotechnology industries are undergoing a huge change. The growing support from governments to launch new drugs to fight several new diseases has augmented the demand for pyrogen testing in the past few decades. Pyrogens are known to cause fever and body ache after being injected. This testing method helps in identifying the presence of endotoxin substances and is being extensively used in the development of new drugs. According to the research report, the global pyrogen testing market is expected to be worth US$1,527.8 mn by the end of 2024 as compared to US$570.0 mn in 2015. During the forecast period of 2016 and 2024, the global market is expected to surge at a CAGR of 11.9%.
Investments in Biotechnology and Pharmaceutical Industries Offer Immeasurable Scope for Growth
The emergence of several biotechnology and pharmaceutical companies across the globe is the primary reason for the growth of the global pyrogen testing market. The growing investments in the development of new drugs to improve healthcare is expected to propel the demand for pyrogen testing. Analysts anticipate that the introduction of innovative drugs and launch of biological products with the rise of chronic diseases and favorable government initiatives will support the growth of the global market. The market is also expected to benefit from the rising awareness about chronic conditions, growing expenditure on healthcare, and favorable reimbursement policies.
Despite the steady market drivers, the global market is expected to be restrained by the ongoing efforts to ban on animal tests. The increasing pressure to stop the usage of rabbits for pyrogen testing is likely to be the key restraining factor in the global market. However, the market could stand to profit from the growing medical tourism across Latin America and Asia Pacific. Furthermore, the emergence of the healthcare industry in emerging economies is anticipated to have a positive impact on the overall market during the forecast period.
North America Poised to Dominate Global Market as Healthcare Garners High Interest in the Region
In terms of geography, the global pyrogen testing market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. In 2015, North America held a dominant share of 38.6% in the global pyrogen testing market. This lion’s share was attributable to the strong presence of key players in the region, who are making big investments in research and development. The report projects that the North America market will continue to thrive as healthcare awareness is on the upswing in the region. During the forecast period, the North America pyrogen testing market is expected to expand at a CAGR of 11.6%. The limulus amebocyte lysate test (LAL) test type segment will be popular over others all across North America as it has been until 2015.
The emerging economies of Asia Pacific such as India, China, and Japan are likely to give the overall market a much-needed impetus as well. Owing to this reason, the Asia Pacific pyrogen testing market is likely to expand at a CAGR of 14.3% during the forecast period.
The key players operating in the global pyrogen testing market are Thermo Fisher Scientific, Inc., Genscript, Hyglos Gmbh, Lonza Group, Associates of Cape Cod, Inc., Wako Chemicals USA, Inc., Sanquin and Charles River Laboratories International, Inc., and Merck & Co., Inc.
Posted by at No comments:
Labels: , , ,

Clostridium Vaccine (Animal Health) Market is expected to reach US$643.5 mn by 2024

The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong financial backing allowing increased focus on research and development activities.
Top companies in the market aim to strengthen their positions with strategies such as targeted in-licensing, acquisition, and innovative marketing. Use of the digital medium to reach out to an extended consumer base and serve the consumer more effectively has also started becoming a popular strategy. An instance is the recent update made to Bayer’s BCS cowdition smartphone application in July 2016. The enhanced application is expected to help veterinarians to track the current and future hurdles regarding cattle health, which will help minimize the impact of metabolic diseases on dairy cows.
Transparency Market Research estimates that the global clostridium vaccines market will exhibit a healthy 4.9% CAGR over the period between 2016 and 2024. Rising at this rate, the market, which valued at US$418.0 mn in 2015, is expected to reach US$643.5 mn by 2024. In terms of animal species, the swine segment presently leads but is expected to be outpaced by the growth of the ovine segment. In terms of geography, the global market is dominated by North America, which accounted for over 37% of the global market in 2015.
Rising Intervention by Government Bodies to Play Key Role in Market Development
Government initiatives play a key role the development of animal health care markets. For instance, the China market for veterinary healthcare is chiefly driven by compulsory immunization policy, several animal health awareness programs, the easy availability of affordable veterinary vaccines, and fund for research and development in the field. In several other developed as well as developing economies, funds invested by government bodies for the research and development of veterinary vaccines and medications play a key role in boosting the demand for clostridium vaccines.
Along with this, the rising global demand for animal products such as cattle milk, meat, and eggs is also a key factor driving the global market for clostridium vaccines. Animal products such as milk, pork, beef, and chicken collectively account for nearly 40% of global agricultural GDP and generated revenues valuing nearly US$600 bn in 2015. The market for these products in developing countries is growing rapidly due to the rising population and increased disposable incomes. The resultant rise in awareness regarding the need for maintaining the excellent health of animals is expected to further drive the clostridium vaccines market in the near future.
High Consumer Dependence on Government Distribution Channels to Hamper Growth
In emerging economies, especially, government bodies play the central role in the distribution of vaccines. The Government of India, for instance, buys clostridium vaccines in bulk from manufacturers and supply them in different regions of the country. Bulk purchase of clostridium vaccines results in reduced prices, resulting in the low profitability of the market thus hampering its overall rate of development.
Moreover, the market's growth is also restrained to vast extent owing to the short exclusivity span of clostridium vaccines. Product exclusivity period in the animal health care industry is mostly only about three years to five years. Shorter exclusivity periods lead to a vast rise in competition from generics and over-the-counter (OTC) products. The increase in generic competition lowers product sales and significantly affects the profitability of the market.
This review of the market is based on a recent market research report published by Transparency Market Research, titled "Clostridium Vaccine (Animal Health) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024."
Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)